Monograph Details
|
|
Neoplasms
> Monoclonal antibodies
|
|
VECTIBIX |
| Manufacturer |
|
Amgen, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Human epidermal growth factor receptor (EGFR) inhibitor. |
| Generic Name |
|
Panitumumab 20mg/mL; soln for IV infusion after dilution; preservative-free. |
| Indications |
|
EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. |
| Children |
|
Not recommended. |
| Adults |
|
6mg/kg by IV infusion over 60 minutes once every 14 days until disease progression detected. Doses >1000mg: infuse over 90 minutes. Infusion reactions or dermatologic toxicity: see literature. |
| Precautions |
|
Test for EGFR protein expression. Withhold or discontinue therapy if severe dermatological toxicities occur; monitor for infection. Permanently discontinue therapy if interstitial lung disease, pneumonitis, or lung infiltrates develop. Limit sun exposure. Monitor magnesium and calcium levels during and for 8 weeks after completing therapy. May impair fertility in women; use effective contraception during treatment and for 6 months following last dose. Pregnancy (Cat.C). Nursing mothers: not recommended; discontinue during therapy and for 2 months after last dose. |
| Interactions |
|
Concomitant irinotecan, bolus 5-fluorouracil, and leucovorin (IFL): not recommended. |
| Adverse Reactions |
|
Skin rash, paronychia, photosensitivity, electrolyte depletion (eg, hypomagnesemia, hypocalcemia), nausea, diarrhea, abdominal pain, constipation, fatigue; severe dermatologic toxicities with possible infection (may be fatal), infusion reactions (stop therapy if severe; may need to permanently discontinue: see literature), pulmonary fibrosis. |
| How Supplied |
|
Single-use vial (5mL, 10mL, 20mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
